Necrotizing Soft Tissue Infections Clinical Trial
Hypothesis: We hypothesize that RNAseq will allow us to learn more about the causative agents
of necrotizing soft tissue infections (NSTI) and risk factors involved in acquiring these
devastating infections
Tissue biopsies will be obtained from consented patients admitted with NSTI. Biopsies will be
used for standard clinical analysis of bacterial species present or stored for later RNA
sequencing. RNA sequencing will identify bacteria that are present within the infection site
that may not be detected using standard culture techniques as well as reveal bacterial gene
expression profiles within the NSTI site. Medical charts will also be reviewed for basic
patient information as well as wound care management practices. We hope to identify bacterial
species commonly present in these types of infections as well as risk factors predisposing
individuals to NSTI's.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01790698 -
Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs).
|
||
| Enrolling by invitation |
NCT02483650 -
Hyperbaric Oxygen Therapy Registry
|
||
| Completed |
NCT01417780 -
Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients
|
Phase 2 | |
| Completed |
NCT02469857 -
Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
|
Phase 3 |